Published in Ir Med J on December 01, 1980
Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother (1968) 14.80
A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). Philos Trans R Soc Lond B Biol Sci (2001) 10.38
A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). Neuroimage (1995) 8.46
Intellectual ability and cortical development in children and adolescents. Nature (2006) 8.41
Incorporating prior knowledge into image registration. Neuroimage (1997) 8.24
Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet (2000) 6.94
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature (1992) 5.56
Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci U S A (2007) 5.56
Comparison of some properties of pronethalol and propranolol. Br J Pharmacol Chemother (1965) 4.71
Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer (1989) 4.34
Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother (2008) 4.21
Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol (1968) 4.20
The pharmacology of beta sympathetic blockade. Am J Cardiol (1966) 3.96
Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging. Neurology (1992) 3.87
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J (2003) 3.55
Alternative strategies for stroke care: a prospective randomised controlled trial. Lancet (2000) 3.27
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation (2001) 3.21
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
Patients with fatigue in general practice: a prospective study. BMJ (1993) 3.14
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology (2008) 3.10
Optical isomers of propranolol. Nature (1966) 3.09
Sequence diversity in 36 candidate genes for cardiovascular disorders. Am J Hum Genet (1999) 3.02
Retrospective evaluation of intersubject brain registration. IEEE Trans Med Imaging (2003) 3.02
Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet (1994) 2.99
The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol (1969) 2.94
Staffing in cardiology in the United Kingdom 1988. Fifth biennial survey. Br Heart J (1989) 2.93
Admission to child health surveillance lists: the views of FHSA general managers and general practitioners. BMJ (1991) 2.82
Bacteriocin production by Clostridium acetobutylicum in an industrial fermentation process. Appl Environ Microbiol (1979) 2.67
A four-dimensional probabilistic atlas of the human brain. J Am Med Inform Assoc (2001) 2.64
Three-dimensional MRI atlas of the human cerebellum in proportional stereotaxic space. Neuroimage (1999) 2.62
Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation (1999) 2.56
The clinical pharmacology of mexiletine. Br J Clin Pharmacol (1978) 2.56
Controlled trial of propranolol in thyrotoxicosis. Lancet (1969) 2.54
The effect of propranolol on the cardiovascular responses to isoprenaline, adrenaline and noradrenaline in the anaesthetized dog. Br J Pharmacol Chemother (1966) 2.52
Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Témoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension (1996) 2.44
The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer (1981) 2.43
Consultation use of a computer by general practitioners. J R Coll Gen Pract (1984) 2.36
Specific involvement of human parietal systems and the amygdala in the perception of biological motion. J Neurosci (1996) 2.33
Underperforming doctors in general practice: a survey of referrals to UK Deaneries. Br J Gen Pract (2001) 2.33
Cardio-selective beta-blockade. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 2.33
Functional imaging of an illusion of pain. Nature (1996) 2.26
Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med (1989) 2.25
Stopping drug treatment of hypertension: experience in 18 British general practices. Br J Gen Pract (1999) 2.22
The effect of Kö 1173, a new anticonvulsant agent on experimental cardiac arrhythmias. Br J Pharmacol (1972) 2.11
Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94. The Scottish Melanoma Group. BMJ (1997) 2.08
Early childhood prolonged febrile convulsions, atrophy and sclerosis of mesial structures, and temporal lobe epilepsy: an MRI volumetric study. Neurology (1993) 2.07
Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction. Lancet (1993) 2.06
Simulated surgery in the summative assessment of general practice training: results of a trial in the Trent and Yorkshire regions. Br J Gen Pract (1998) 2.05
MRI volumetric measurement of amygdala and hippocampus in temporal lobe epilepsy. Neurology (1993) 2.04
The successful development of decentralised health service management: an evaluation of area health services in New South Wales. Aust Health Rev (1992) 1.97
Impact of NHS direct on demand for immediate care. Target communities show poor awareness of NHS direct. BMJ (2000) 1.96
The clinical pharmacology of beta adrenergic blocking drugs. J R Coll Physicians Lond (1976) 1.94
National Poisons Information Services: report and comment 1980. Br Med J (Clin Res Ed) (1981) 1.91
Oral mexiletine in high-risk patients after myocardial infarction. Lancet (1981) 1.91
Effect of computer use in the consultation on the delivery of care. Br Med J (Clin Res Ed) (1985) 1.90
The peripheral vascular effects of propranolol and related compounds. Br J Pharmacol Chemother (1967) 1.87
Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet (1994) 1.85
The effect of experimental cardiac arrhythmias of a new anticonvulsant agent, Kö 1173, and its comparison with phenytoin and procainamide. Br J Pharmacol (1970) 1.81
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther (1974) 1.81
Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. Arch Gen Psychiatry (1999) 1.78
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
X-ray refraction effects: application to the imaging of biological tissues. Br J Radiol (2003) 1.73
An interactive computerized protocol for the management of hypertension: effects on the general practitioner's clinical behaviour. J R Coll Gen Pract (1986) 1.72
Optimal screening mammography reading volumes; evidence from real life in the East Midlands region of the NHS Breast Screening Programme. Clin Radiol (2010) 1.72
Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol (1976) 1.71
Medicaid managed care in thirteen states. Health Aff (Millwood) (1998) 1.71
Trends in cigarette smoking in 36 populations from the early 1980s to the mid-1990s: findings from the WHO MONICA Project. Am J Public Health (2001) 1.69
Mexiletine (Kö 1173) in the management of ventricular dysrhythmias. Lancet (1973) 1.68
Some pharmacological properties of a new adrenergic beta-receptor antagonist. Nature (1966) 1.66
Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol (1985) 1.65
Care-seeking among individuals with chronic low back pain. Spine (Phila Pa 1976) (1995) 1.63
Propranolol and the utilization of radioiodine by the human thyroid gland. Acta Endocrinol (Copenh) (1969) 1.63
Effect of propranolol on arrhythmias following coronary artery occlusion in dogs. Cardiovasc Res (1967) 1.61
Neonatal thyrotoxicosis treated with propranolol. Arch Dis Child (1974) 1.59
Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry (1995) 1.59
Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol. Eur J Clin Pharmacol (1980) 1.57
Practolol in acute myocardial infarction. Acta Med Scand Suppl (1976) 1.57
Systemic chemokine levels, coronary heart disease, and ischemic stroke events: the PRIME study. Neurology (2011) 1.57
Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: a double-blind, randomized, factorial-design, controlled trial. Am J Clin Nutr (1998) 1.56
Evaluation of a library program in a Carnegie model area health education center. Bull Med Libr Assoc (1978) 1.55
Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol (1980) 1.55
Emergency department admissions to inpatient cardiac telemetry beds: a prospective cohort study of risk stratification and outcomes. Am J Med (2001) 1.54
The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis (2001) 1.53
Management of metabolic acidosis in acute gastro-enteritis. Br Med J (1966) 1.53
Patients who consult with tiredness: frequency of consultation, perceived causes of tiredness and its association with psychological distress. Br J Gen Pract (1994) 1.53
Leisure-time physical activity and regular walking or cycling to work are associated with adiposity and 5 y weight gain in middle-aged men: the PRIME Study. Int J Obes Relat Metab Disord (2001) 1.53
Repeat HIV testing: high-risk behaviour or risk reduction strategy? AIDS (2000) 1.52
Reliability of reported family history of myocardial infarction. BMJ (1993) 1.52
Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation (2004) 1.52
Stimulation of adrenergic beta-receptors by orciprenaline. Br Med J (1967) 1.52
Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation (2005) 1.52
Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases. Eur J Clin Invest (2001) 1.51
Human sealpox resulting from a seal bite: confirmation that sealpox virus is zoonotic. Br J Dermatol (2005) 1.51
New polymorphisms in the interleukin-10 gene--relationships to myocardial infarction. Eur J Clin Invest (2001) 1.50
Pigtail catheter drain in the treatment of empyema thoracis. Arch Dis Child (2002) 1.50
Vacuum-assisted excision of breast lesions of uncertain malignant potential (B3) - an alternative to surgery in selected cases. Breast (2008) 1.48
Staffing in cardiology in the United Kingdom 1990. Sixth biennial survey: with data on facilities in cardiology in England and Wales 1989. Br Heart J (1991) 1.48